DeBogy Molecular
Biotechnology company developing surface-modification technologies that permanently alter material surfaces to provide contact-active antimicrobial activity. Focus areas include engineering treated surfaces for medical devices and a range of industrial and consumer materials, with preclinical data supporting efficacy and biocompatibility.
Industries
Nr. of Employees
small (1-50)
DeBogy Molecular
Battle Creek, Michigan, United States, North America
Patents
Methods of use and processes for preparing alcoholic solutions of polyvinylpyridine polymers
US-12290072-B2
View DetailsMethods of use and processes for preparing alcoholic solutions of polyvinylpyridine polymers
US-11019819-B2
View DetailsMethods of use and processes for preparing alcoholic solutions of polyvinylpyridine polymers
US-10743539-B2
View DetailsReady-to-use storable methanolic solution of a biocompatible and biocidal polyvinylpyridine polymer
US-10238110-B2
View Details
Methods of use and processes for preparing alcoholic solutions of polyvinylpyridine polymers
US-12290072-B2
View DetailsMethods of use and processes for preparing alcoholic solutions of polyvinylpyridine polymers
US-11019819-B2
View DetailsMethods of use and processes for preparing alcoholic solutions of polyvinylpyridine polymers
US-10743539-B2
View DetailsReady-to-use storable methanolic solution of a biocompatible and biocidal polyvinylpyridine polymer
US-10238110-B2
View DetailsProducts
Proprietary surface-modification platform
A molecular platform designed to modify material surfaces to exert contact-active antimicrobial effects across a range of substrates.
DeBogy-treated titanium implants
Titanium implants treated with DeBogy Molecular's antimicrobial surface modification technology to reduce bacterial biofilm formation by 99.9% without antibiotics or toxic chemicals.
DeBogy Molecular Antimicrobial Surface Modification Platform
A versatile platform that permanently modifies surface structures to destroy viral, bacterial, and fungal cells on contact, rendering a wide range of materials 99.99% permanently biocidal.
Proprietary surface-modification platform
A molecular platform designed to modify material surfaces to exert contact-active antimicrobial effects across a range of substrates.
DeBogy-treated titanium implants
Titanium implants treated with DeBogy Molecular's antimicrobial surface modification technology to reduce bacterial biofilm formation by 99.9% without antibiotics or toxic chemicals.
DeBogy Molecular Antimicrobial Surface Modification Platform
A versatile platform that permanently modifies surface structures to destroy viral, bacterial, and fungal cells on contact, rendering a wide range of materials 99.99% permanently biocidal.
Services
Surface-treatment services and technology for imparting contact-active antimicrobial properties to a range of substrates for medical, textile and industrial applications.
A platform of proprietary molecules intended to be immobilized on material surfaces to provide permanent biocidal activity without soluble antibiotics or toxic additives.
Coordination and commissioning of external CROs for animal-model testing of surface-treated devices.
Surface-treatment services and technology for imparting contact-active antimicrobial properties to a range of substrates for medical, textile and industrial applications.
A platform of proprietary molecules intended to be immobilized on material surfaces to provide permanent biocidal activity without soluble antibiotics or toxic additives.
Coordination and commissioning of external CROs for animal-model testing of surface-treated devices.
Expertise Areas
- Surface modification and functionalization
- Antimicrobial materials development
- Preclinical in vivo testing for implant-associated infection
- Biocompatibility assessment
Key Technologies
- Surface chemical functionalization
- Immobilized antimicrobial molecular agents
- Electrostatic microbial membrane disruption
- Preclinical in vivo biofilm models
News & Updates
Preclinical in vivo study reporting substantial reductions in bacterial biofilm and surrounding tissue bacterial load on treated implants versus control; study used a high MRSA inoculum in a mouse model.
In a mouse implant model, treated titanium implants showed a 99.97% reduction in bacterial biofilm vs untreated control at 7 days; surrounding tissue bacterial load reduced by 99.8% with improved local tissue histology and reported biocompatibility.
Preclinical in vivo study reporting substantial reductions in bacterial biofilm and surrounding tissue bacterial load on treated implants versus control; study used a high MRSA inoculum in a mouse model.
In a mouse implant model, treated titanium implants showed a 99.97% reduction in bacterial biofilm vs untreated control at 7 days; surrounding tissue bacterial load reduced by 99.8% with improved local tissue histology and reported biocompatibility.